Fortress Biotech 9.375% Series A Preferred Stock
FBIOP
0 hedge funds and large institutions have $0 invested in Fortress Biotech 9.375% Series A Preferred Stock in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
0.44% less ownership
Funds ownership: 0.44% → 0% (-0.44%)
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $262K → $0 (-$262K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Shikiar Asset Management
New York
|
-$262K |
FBIOP Hedge Fund Activity: Q3 2023 in Review
0 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) for Q3 2023, worth a combined $0 — down 100% from $262K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of FBIOP and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Shikiar Asset Management, exiting entirely with an estimated $262K sold.
- 0 institutional investors held Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) as of Q3 2023, down from 1 in Q2 2023.
- Funds reported $0 of Fortress Biotech 9.375% Series A Preferred Stock stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new Fortress Biotech 9.375% Series A Preferred Stock positions in Q3 2023 and 1 closed out, a net change of -1 holder.
- The largest Fortress Biotech 9.375% Series A Preferred Stock seller in Q3 2023 was Shikiar Asset Management, an estimated $262K sold.
Based on aggregated 13F filings for Q3 2023.